Valuation: Gennex Laboratories Limited

Market Cap 1.73B 18.15M 15.77M 14.68M 13.48M 25.46M 25.85M 173M 67.92M 862M 68.15M 66.65M 2.89B P/E 2024
26x
P/E 2025 15.4x
Enterprise Value 1.46B 15.27M 13.27M 12.35M 11.34M 21.42M 21.75M 146M 57.15M 726M 57.34M 56.08M 2.43B EV / Sales 2024
3.67x
EV / Sales 2025 1.79x
Free-Float
65.03%
Yield 2024 *
-
Yield 2025 -
05-30 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-14 Gennex Laboratories Limited Resignation of Shilpa Bung, Non-Executive Independent Women Director, Effective February 14, 2026 CI
02-14 Gennex Laboratories Limited Appoints Khushbu Kachhawa as Additional Director (Non-Executive Independent Women Director) CI
02-14 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-14 Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
14/08/25 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
30/05/25 Gennex Laboratories Limited Announces Resignation of Dr. Sch Dharma Rao as Non-Executive Non-Independent Director, Effective May 30, 2025 CI
30/05/25 Gennex Laboratories Limited Appoints Sandeep Kumar Daga as Non-Executive Non-Independent Director CI
30/05/25 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
14/02/25 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
14/02/25 Gennex Laboratories Limited Announces Resignation of Mohammed Khaleequr Rahman as Non-Executive Non-Independent Director CI
14/11/24 Gennex Laboratories Limited Approves the Appointment of Akkali Santosh Kumar as Chief Financial Officer CI
01/10/24 Gennex Laboratories Limited Announces Board Changes CI
1 day+0.91%
1 week-2.32%
Current month-17.35%
1 month-17.35%
3 months-11.31%
6 months-27.97%
Current year-38.04%
1 week 8.25
Extreme 8.25
9.25
1 month 8.25
Extreme 8.25
10.85
Current year 7.05
Extreme 7.05
14.77
1 year 7.05
Extreme 7.05
17.25
3 years 6.86
Extreme 6.86
29
5 years 4.81
Extreme 4.81
29
10 years 1.32
Extreme 1.32
29
Manager TitleAgeSince
Chief Executive Officer 40 17/05/2012
Director of Finance/CFO - 11/11/2024
Compliance Officer 62 19/04/2023
Director TitleAgeSince
Chairman 40 -
Director/Board Member - 20/12/2020
Director/Board Member - 20/12/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.91%-2.32%-31.32%+32.24% 22.34M
-0.53%-3.95%+55.23%+152.74% 1,030B
+0.21%-2.68%+55.61%+53.02% 617B
-2.51%-3.25%+32.76%+67.76% 455B
+0.06%+1.17%+36.21%+31.25% 350B
-0.14%-0.83%+33.24%+40.28% 299B
-0.69%-0.44%+9.86%+14.23% 265B
-7.37%-4.31%-5.69%-41.99% 225B
-0.64%+2.43%+30.52%+64.49% 209B
-0.82%+0.70%+15.96%+71.01% 163B
Average -0.90%+4.15%+23.24%+48.50% 361.27B
Weighted average by Cap. -0.76%+4.87%+38.47%+72.84%

Financials

2024 2025
Net sales 867M 9.08M 7.9M 7.35M 6.75M 12.74M 12.94M 86.64M 34M 432M 34.12M 33.37M 1.45B 1.38B 14.45M 12.56M 11.69M 10.73M 20.27M 20.58M 138M 54.07M 687M 54.25M 53.06M 2.3B
Net income 132M 1.38M 1.2M 1.12M 1.03M 1.94M 1.97M 13.16M 5.17M 65.59M 5.18M 5.07M 220M 181M 1.9M 1.65M 1.54M 1.41M 2.66M 2.7M 18.11M 7.11M 90.22M 7.13M 6.97M 303M
Net Debt -413M -4.33M -3.76M -3.5M -3.21M -6.07M -6.16M -41.26M -16.19M -206M -16.25M -15.89M -689M -275M -2.88M -2.5M -2.33M -2.14M -4.04M -4.1M -27.45M -10.77M -137M -10.81M -10.57M -459M
Logo Gennex Laboratories Limited
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing of bulk drugs and intermediaries. It offers products in various therapeutic categories, including expectorant (mucolyte), relaxant (skeletal muscle relaxant), antihistamines, urinary tract analgesic, antifungals called triazoles, tricyclic antidepressant, acting muscle relaxants, muscle relaxant, selective serotonin reuptake inhibitors (SSRIS), and xanthine oxidase inhibitors. Its products include Guaifenesin, Methocarbamol, Fexofenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl and Allopurinol. The Company has manufacturing facilities in India which cater to both domestic and international markets. Its international markets include Bangladesh, Bolivia, China, Colombia, Costa Rica, Cuba, Germany, Indonesia, Iran, Iraq, Israel, Jordan, Kenya, South Korea, Malaysia and Mexico.
Employees
115
Date Price Change Volume
31/07/26 8.860 +0.91% 341,834
30/07/26 ₹8.780 -1.01% 194,739
29/07/26 ₹8.870 -1.33% 337,907
28/07/26 ₹8.990 +0.78% 167,369
27/07/26 ₹8.920 -1.76% 692,535
  1. Stock Market
  2. Stocks
  3. GENNEX6 Stock